Compare AbbVie Inc (ABBV) vs T-Rex 2X Inverse MSTR Daily Target ETF (MSTZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs T-Rex 2X Inverse MSTR Daily Target ETF — how do they compare? AbbVie Inc trades at $249.69 (market cap $441.94B), while T-Rex 2X Inverse MSTR Daily Target ETF trades at $11.31. The key difference: AbbVie Inc pays a 2.77% dividend while T-Rex 2X Inverse MSTR Daily Target ETF pays none, and AbbVie Inc is trading nearer its 52-week high, T-Rex 2X Inverse MSTR Daily Target ETF nearer its low. Which is the better fit depends on your goals.
| ABBV | MSTZ | |
|---|---|---|
Market Cap | $441.94B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $263.58 | $27.92 |
52-Week Low | $197.38 | $3.88 |
Enterprise Value | $506.19B | — |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $247.91, up 0.76% today, with a bullish technical signal and strong analyst support. Recent earnings beats and a 70.73% buy consensus highlight robust fundamentals, driven by Skyrizi and Rinvoq growth offsetting Humira declines. Positive news includes Phase 2 ovarian cancer data and institutional stake increases, reinforcing momentum.
Outlook remains positive with a $278.69 price target, though risks include patent cliffs and debt levels. Revenue growth and dividend stability offer appeal, but investors should monitor competitive pressures and regulatory developments for sustained performance.
MSTZ trades at $11.09, up 2.5% today, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. Key financial ratios are unavailable, limiting fundamental clarity. Recent news highlights ETF performance unrelated to MSTZ, with no direct company updates found.
The outlook remains cautious due to weak technical momentum and lack of fundamental data. Risks include market volatility and unverified financial health. Investors need current earnings reports and analyst coverage to assess opportunities amid the bearish technical setup.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About T-Rex 2X Inverse MSTR Daily Target ETF
MSTZ is a leveraged ETF that seeks daily investment results corresponding to 200% of the inverse (opposite) of the daily performance of the MicroStrategy Incorporated (MSTR) stock. It is designed as a tactical tool for experienced traders to take a bearish position on MSTR, a company known for its large Bitcoin holdings. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment, as its performance over longer periods may significantly deviate from its stated daily objective.
Read more on MSTZ →
